RU2011146654A - Способы лечения рака яичников с применением конъюгированного средства - Google Patents

Способы лечения рака яичников с применением конъюгированного средства Download PDF

Info

Publication number
RU2011146654A
RU2011146654A RU2011146654/15A RU2011146654A RU2011146654A RU 2011146654 A RU2011146654 A RU 2011146654A RU 2011146654/15 A RU2011146654/15 A RU 2011146654/15A RU 2011146654 A RU2011146654 A RU 2011146654A RU 2011146654 A RU2011146654 A RU 2011146654A
Authority
RU
Russia
Prior art keywords
specified
malignant tumor
patient
conjugate
seq
Prior art date
Application number
RU2011146654/15A
Other languages
English (en)
Inventor
Жан-Поль КАСТАН
Мишель ДЕМОЛЕ
Бетти ЛОУРЕНС
Original Assignee
Ангиокем Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ангиокем Инк. filed Critical Ангиокем Инк.
Publication of RU2011146654A publication Critical patent/RU2011146654A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

1. Способ лечения пациента со злокачественной опухолью, которая происходит из яичника, указанный способ включает введение указанному пациенту эффективного количества конъюгата, содержащего:(а) противоопухолевое средство; и(б) полипептид, содержащий аминокислотную последовательность, по крайней мере, на 80% идентичную TFFYGGSRGKRNNFKTEEY (SEQ ID NO:97), где указанный полипептид конъюгирован с указанным противоопухолевым средством.2. Способ по п.1, в котором противоопухолевое средство выбрано из группы, состоящей из паклитаксела, винбластина, винкристина, этопозида, доксорубицина циклофосфамида, таксотера, мелфалана и хлорамбуцила.3. Способ по п.2, в котором указанное противоопухолевое средство представляет собой паклитаксел.4. Способ по любому из пп.1-3, в котором указанный полипептид содержит аминокислотную последовательность, по крайней мере, на 90% идентичную последовательности SEQ ID NO:97.5. Способ по п.4, в котором указанный полипептид содержит аминокислотную последовательность SEQ ID NO:97.6. Способ по п.5, в котором указанный полипептид состоит из аминокислотной последовательности SEQ ID NO:97.7. Способ по п.1, в котором указанный конъюгат вводят в дозе от 100 мг/ми 2000 мг/м.8. Способ по п.7, в котором указанный конъюгат вводят в дозе 300 мг/мдо 1000 мг/м.9. Способ по п.1, в котором указанный конъюгат вводят внутривенно.10. Способ по п.1, в котором указанная злокачественная опухоль метастазировала по крайней мере, в одно место вне яичника и указанный способ эффективен в лечении указанных метастазов.11. Способ по п.10, в котором указанная злокачественная опухоль метастазировала, по крайней мере, в одно место вне головного мозга указанного пациента.12. Способ по

Claims (24)

1. Способ лечения пациента со злокачественной опухолью, которая происходит из яичника, указанный способ включает введение указанному пациенту эффективного количества конъюгата, содержащего:
(а) противоопухолевое средство; и
(б) полипептид, содержащий аминокислотную последовательность, по крайней мере, на 80% идентичную TFFYGGSRGKRNNFKTEEY (SEQ ID NO:97), где указанный полипептид конъюгирован с указанным противоопухолевым средством.
2. Способ по п.1, в котором противоопухолевое средство выбрано из группы, состоящей из паклитаксела, винбластина, винкристина, этопозида, доксорубицина циклофосфамида, таксотера, мелфалана и хлорамбуцила.
3. Способ по п.2, в котором указанное противоопухолевое средство представляет собой паклитаксел.
4. Способ по любому из пп.1-3, в котором указанный полипептид содержит аминокислотную последовательность, по крайней мере, на 90% идентичную последовательности SEQ ID NO:97.
5. Способ по п.4, в котором указанный полипептид содержит аминокислотную последовательность SEQ ID NO:97.
6. Способ по п.5, в котором указанный полипептид состоит из аминокислотной последовательности SEQ ID NO:97.
7. Способ по п.1, в котором указанный конъюгат вводят в дозе от 100 мг/м2 и 2000 мг/м2.
8. Способ по п.7, в котором указанный конъюгат вводят в дозе 300 мг/м2 до 1000 мг/м2.
9. Способ по п.1, в котором указанный конъюгат вводят внутривенно.
10. Способ по п.1, в котором указанная злокачественная опухоль метастазировала по крайней мере, в одно место вне яичника и указанный способ эффективен в лечении указанных метастазов.
11. Способ по п.10, в котором указанная злокачественная опухоль метастазировала, по крайней мере, в одно место вне головного мозга указанного пациента.
12. Способ по п.10, в котором указанная злокачественная опухоль метастазировала вне области таза указанного пациента.
13. Способ по п.10, в котором указанная злокачественная опухоль метастазировала в головной мозг, легкие, печень или их сочетание.
14. Способ по п.10, в котором указанная злокачественная опухоль метастазировала в лимфатическую систему.
15. Способ по п.1, в котором указанная злокачественная опухоль включает в себя клетки идентифицируемые как резистентные к действию лекарственных средств.
16. Способ по п.15, в котором указанная злокачественная клетка экспрессирует MDR1.
17. Способ по п.15 или 16, в котором указанные клетки резистентны к лечению пакпитакселом или к лечению производным таксана.
18. Способ по п.1, в котором указанный способ дополнительно включает применение другой противоопухолевой терапии.
19. Способ по п.1, в котором указанный пациент ранее принимал другое химиотерапевтическое средство.
20. Способ по п.19, в котором указанная злокачественная опухоль является резистентной к указанному ранее принимаемому химиотерапевтическому средству.
21. Способ по п.19 или 20, в котором указанное ранее принимаемое химиотерапевтическое средство представляет собой паклитаксел, средство на основе платины, алкилирующий агент или их сочетание.
22. Способ по п.21, в котором указанное средство на основе платины представляет собой карбоплатин или цисплатин.
23. Способ по п.21, в котором указанный пациент ранее получал комбинированную терапию карбоплатин-паклитакселом.
24. Способ по п.1, в котором указанная злокачественная опухоль представляет собой эпителиальную карциному яичников, или аденокарциному яичников, или ее метастазирующую форму.
RU2011146654/15A 2009-04-20 2010-04-20 Способы лечения рака яичников с применением конъюгированного средства RU2011146654A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17104009P 2009-04-20 2009-04-20
US61/171,040 2009-04-20
PCT/CA2010/000618 WO2010121379A1 (en) 2009-04-20 2010-04-20 Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog

Publications (1)

Publication Number Publication Date
RU2011146654A true RU2011146654A (ru) 2013-05-27

Family

ID=43010638

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011146654/15A RU2011146654A (ru) 2009-04-20 2010-04-20 Способы лечения рака яичников с применением конъюгированного средства

Country Status (12)

Country Link
US (1) US9173891B2 (ru)
EP (1) EP2421562B1 (ru)
JP (1) JP2012524030A (ru)
CN (1) CN102510759A (ru)
AU (1) AU2010239069B2 (ru)
BR (1) BRPI1015295A2 (ru)
CA (1) CA2759129C (ru)
ES (1) ES2729261T3 (ru)
MX (1) MX2011011023A (ru)
RU (1) RU2011146654A (ru)
WO (1) WO2010121379A1 (ru)
ZA (1) ZA201107626B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE512674T1 (de) 2003-01-06 2011-07-15 Angiochem Inc Angiopep-1, verwandte verbindungen, und deren verwnedungen
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
EP2233156B1 (en) 2005-07-15 2013-05-01 Angiochem Inc. Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
EP2074142A4 (en) 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
AU2009322043A1 (en) 2008-12-05 2011-07-07 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
AU2009327267A1 (en) 2008-12-17 2011-07-14 Angiochem, Inc. Membrane type-1 matrix metalloprotein inhibitors and uses thereof
EP2421562B1 (en) 2009-04-20 2019-03-13 Angiochem Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
CN102596993A (zh) 2009-07-02 2012-07-18 安吉奥开米公司 多聚体肽结合物以及其应用
CA2881602A1 (en) 2012-08-14 2014-02-20 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
US20160106856A1 (en) * 2012-08-14 2016-04-21 Angiochem Inc. Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
DK2917244T3 (da) * 2012-11-12 2021-03-08 Angiochem Inc Aprotinin-afledte polypeptid-antistofkonjugater
WO2016061801A1 (zh) * 2014-10-24 2016-04-28 中国科学技术大学 用于淀粉样蛋白显像的血管肽及其衍生物
CN105585614B (zh) * 2014-10-24 2019-06-07 中国科学技术大学 用于淀粉样蛋白显像的血管肽及其衍生物
CA2989400A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Ang1005 for the treatment of leptomeningeal carcinomatosis
WO2020036987A1 (en) 2018-08-13 2020-02-20 Signablok, Inc. Peptides and compositions for targeted treatment and imaging
EP4000613A1 (en) 2020-11-19 2022-05-25 Polyphor Ag Pharmaceutical combinations comprising a peptide cxcr4 inhibitor and a taxane for treating cancer
MX2023005829A (es) 2020-11-19 2023-08-21 Spexis Ag Combinaciones farmaceuticas para tratar el cancer.
EP4223292A1 (en) 2022-02-07 2023-08-09 Cellestia Biotech AG Pharmaceutical combinations for treating cancer

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
NZ219609A (en) 1986-03-13 1990-09-26 Univ Monash Assay methods for inhibin
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4904768A (en) 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
GB2208511A (en) 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
US4942184A (en) 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5632990A (en) 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
US5258499A (en) 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5028697A (en) 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5169933A (en) 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5948634A (en) 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
DE3912638A1 (de) 1989-04-18 1990-10-31 Bayer Ag Gentechnologisch hergestellte homologe des alzheimer protease inhibitors, wirtstaemme sowie expressionsvektoren fuer ihre herstellung und ihre verwendung als arzneimittel
US5126249A (en) 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US6475781B1 (en) 1990-05-17 2002-11-05 Dana-Farber Cancer Institute, Inc. Trans-dominant suppressor genes for oligomeric proteins
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
GB9017008D0 (en) 1990-08-02 1990-09-19 Erba Carlo Spa Process for the enzymatic preparation of basic fibroblast growth factor
US6495513B1 (en) 1991-03-11 2002-12-17 Curis, Inc. Morphogen-enhanced survival and repair of neural cells
US5955444A (en) 1991-08-09 1999-09-21 Massachusetts Institute Of Technology Method of inhibiting abnormal tau hyper phosphorylation in a cell
US5627270A (en) 1991-12-13 1997-05-06 Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5204354A (en) 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
CA2145517A1 (en) 1992-09-25 1994-04-14 Ignace Lasters Bovine pancreatic trypsin inhibitor derived inhibitors of factor viia - tissue factor complex
EP0599303A3 (en) 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
WO1994019692A1 (en) 1993-02-18 1994-09-01 The General Hospital Corporation Alzheimer's disease therapeutics
WO1996031531A2 (en) 1995-04-04 1996-10-10 Advanced Bioconcept, Inc. Fluorescent peptides
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
EP0827539A2 (en) 1995-05-08 1998-03-11 Scios Inc. Kunitz type protease inhibitors
AU5908296A (en) 1995-05-31 1996-12-24 Fred Hutchinson Cancer Research Center Compositions and methods for targeted delivery of effector m olecules
US5780265A (en) 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
NZ331540A (en) 1996-03-11 1999-10-28 Bayer Ag Human bikunin
WO1997040160A1 (en) 1996-04-24 1997-10-30 Rijksuniversiteit Te Groningen A prokaryotic protein having functional and structural homology with the human p-glycoprotein encoded by the mdr-1 gene, nucleic acids encoding and cells expressing said protein
EP0966303A2 (en) 1996-05-01 1999-12-29 Antivirals Inc. Polypeptide conjugates for transporting substances across cell membranes
DE19636889A1 (de) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
AU4907897A (en) 1996-10-11 1998-05-11 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
CA2283474A1 (en) 1997-03-04 1998-09-11 Bio-Technology General Corp. Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
GB9705903D0 (en) 1997-03-21 1997-05-07 Elliott Gillian D VP22 Proteins and uses thereof
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
JP2002502376A (ja) 1997-05-21 2002-01-22 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 生物学的膜を横切る輸送を増強するための組成物および方法
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US6475481B2 (en) 1997-11-18 2002-11-05 Canji Inc Purging of stem cell products
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US5981564A (en) 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US5922754A (en) 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
JP4808846B2 (ja) 1999-02-24 2011-11-02 ザ ユーエイビー リサーチ ファンデイション 癌の標的付けられた治療のためのタキサン誘導体
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
CA2385882C (en) 1999-09-24 2009-11-24 Genentech, Inc. Tyrosine derivatives
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
DE19953696A1 (de) 1999-11-09 2001-05-10 Alexander Cherkasky Selektive proteolytische Synzyme (SPS)
CA2355334A1 (en) 2000-10-16 2002-04-16 Procyon Biopharma Inc. Pharmaceutical preparations and methods for inhibiting tumors
WO2002043765A2 (en) 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
ES2311560T3 (es) 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
WO2002076448A1 (en) 2001-03-23 2002-10-03 Napro Biotherapeutics, Inc. Molecular conjugates for use in treatment of cancer
DK1456360T3 (en) 2001-04-19 2015-08-31 Scripps Research Inst Methods and Composition for Preparation of Orthogonal TRNA-Aminoacyl-TRNA Synthetase Pairs
US20030170891A1 (en) 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US7192921B2 (en) 2001-11-08 2007-03-20 The Burnham Institute Peptides that home to tumor lymphatic vasculature and methods of using same
DE60314495T2 (de) 2002-02-07 2008-03-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Aminosäuresequenzen, die in der lage sind die durchdringung einer biologischen barriere zu erleichtern
AU2003218815A1 (en) 2002-03-29 2003-12-02 Creagene Inc. Cytoplasmic transduction peptides and uses thereof
US6881829B2 (en) 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
AU2003237314B2 (en) 2002-05-29 2010-03-04 Biomarin Pharmaceutical Inc. Targeted therapeutic proteins
AU2003279750A1 (en) 2002-06-28 2004-01-19 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
JP2006507841A (ja) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US20040102369A1 (en) 2002-11-27 2004-05-27 The Regents Of The University Of California Transport of basic fibroblast growth factor across the blood brain barrier
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7319090B2 (en) 2002-11-27 2008-01-15 University Of North Carolina At Chapel Hill Methods of treating cerebral ischemia
ATE512674T1 (de) 2003-01-06 2011-07-15 Angiochem Inc Angiopep-1, verwandte verbindungen, und deren verwnedungen
US20040162284A1 (en) 2003-02-19 2004-08-19 Harris Herbert W. Method of lowering body temperature with (S) tofisopam
DK2368554T3 (en) 2003-04-08 2015-01-26 Progenics Pharm Inc A pharmaceutical composition comprising methylnaltrexone
KR101184833B1 (ko) 2003-04-08 2012-09-20 바이오템프트, 비.브이. Ｈｃｇ 절편들을 포함하는 점막 및 경구 투여용 조성물
ES2702942T3 (es) 2003-04-17 2019-03-06 Alnylam Pharmaceuticals Inc Agentes de ARNi modificados
AU2003286870A1 (en) 2003-06-05 2005-01-04 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
CA2525236C (en) 2003-06-20 2015-03-24 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
WO2005014625A1 (ja) 2003-08-08 2005-02-17 Tissue Targeting Japan Inc. 脳移行活性を有するポリペプチド、およびその利用
JP2007512001A (ja) 2003-08-28 2007-05-17 バイオレクシス ファーマシューティカル コーポレイション Ｅｐｏミメティックペプチドおよび融合タンパク質
US20050058702A1 (en) 2003-09-17 2005-03-17 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
US20050208095A1 (en) 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US7208174B2 (en) 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
EP1771573A4 (en) 2004-07-21 2009-02-18 Ambrx Inc BIOSYNTHETIC POLYPEPTIDES OBTAINED FROM NON-NATURALLY CITED AMINO ACIDS
KR20090006221A (ko) 2004-07-26 2009-01-14 아스테리온 리미티드 연결체들
WO2006039253A2 (en) 2004-09-29 2006-04-13 Children's Memorial Hospital Sirna-mediated gene silencing of alpha synuclein
US9002652B1 (en) 2005-01-27 2015-04-07 Institute For Systems Biology Methods for identifying and using organ-specific proteins in blood
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
HUE038768T2 (hu) 2005-02-18 2018-11-28 Abraxis Bioscience Llc Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia
ES2383901T5 (es) 2005-02-18 2015-02-25 Angiochem Inc. Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro
EP1877099B1 (en) 2005-04-06 2012-09-19 Genzyme Corporation Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety
US20090246211A1 (en) 2005-05-12 2009-10-01 Henri John T Molecular constructs suitable for targeted conjugates
WO2006138343A2 (en) 2005-06-14 2006-12-28 Raptor Pharmaceutical Inc. Compositions comprising receptor - associated protein (rap) variants specific for lrp2 and uses thereof
EP2233156B1 (en) * 2005-07-15 2013-05-01 Angiochem Inc. Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
CA2615617A1 (en) 2005-07-19 2007-01-25 The Board Of Trustees Of The University Of Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof
GB0517092D0 (en) 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
JP2009507852A (ja) 2005-09-08 2009-02-26 エムディーアールエヌエー，インコーポレイテッド リボ核酸の細胞への送達用医薬組成物
JP2009508494A (ja) 2005-09-16 2009-03-05 ラプトール ファーマシューティカル インコーポレイテッド Ｃｒを含むタンパク質に対して特異的な受容体−結合タンパク質（ｒａｐ）変異体を含む組成物およびその使用
US8142781B2 (en) 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
EP2202239A1 (en) 2005-11-01 2010-06-30 Alnylam Pharmaceuticals Inc. RNAI inhibition of influenza virus replication
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
US8290433B2 (en) 2007-11-14 2012-10-16 Blaze Mobile, Inc. Method and system for securing transactions made through a mobile communication device
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
WO2007103455A2 (en) 2006-03-06 2007-09-13 Amunix, Inc. Genetic packages and uses thereof
US7477504B1 (en) 2006-03-13 2009-01-13 C.P.D. Technologies, Inc. Versatile stun glove
UA94734C2 (ru) 2006-03-30 2011-06-10 Глаксо Груп Лимитед ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
JP2009543806A (ja) 2006-07-13 2009-12-10 バーナム インスティテュート フォー メディカル リサーチ ｇＣ１ｑＲ／ｐ３２を標的化するための方法および組成物
ATE524493T1 (de) 2006-07-24 2011-09-15 Biorexis Pharmaceutical Corp Exendin-fusionsproteine
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
EP2074142A4 (en) 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
WO2008069876A2 (en) 2006-10-27 2008-06-12 University Of Kentucky Research Foundation Amidated dopamine neuron stimulating peptides for cns dopaminergic upregulation
US9399675B2 (en) 2007-02-28 2016-07-26 The Board Of Regents Of The University Of Oklahoma Methods and compositions for diagnosing Alzheimer's disease and age-related macular degeneration
KR101801454B1 (ko) 2007-03-21 2017-11-24 랩터 파마슈티컬스 인코포레이티드 환형의 수용체-연관된 단백질(ｒａｐ) 펩티드
EP2164866B1 (en) 2007-05-29 2014-05-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
WO2009039188A1 (en) 2007-09-17 2009-03-26 Ludwig Institute For Cancer Research Ltd Peptides and methods for the treatment of gliomas and other cancers
CN101939027B (zh) 2007-10-02 2014-07-30 玛瑞纳生物技术有限公司 用于递送核酸的脂肽
WO2009070597A2 (en) 2007-11-26 2009-06-04 Armagen Technologies, Inc. Fusion proteins for delivery of gdnf to the cns
MX2010006925A (es) 2007-12-20 2011-05-02 Angiochem Inc Conjugados de polipeptido-acido nucleico y sus usos.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CN102016058A (zh) 2008-02-21 2011-04-13 伯纳姆医学研究所 与具有c端元件的肽和蛋白相关的方法和组合物
ES2721148T3 (es) 2008-04-18 2019-07-29 Angiochem Inc Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel y métodos relacionados de preparación y uso
CN102245636A (zh) 2008-10-15 2011-11-16 安吉奥开米公司 用于药物递送的依托泊苷和多柔比星结合物
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
EP2370472A4 (en) 2008-12-05 2013-04-24 Angiochem Inc LEPTIN AND LEPTIN ANALOGUE CONJUGATES AND ITS USES
AU2009322043A1 (en) 2008-12-05 2011-07-07 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
JP2012510798A (ja) 2008-12-05 2012-05-17 アンジオケム インコーポレーテッド ペプチド治療剤コンジュゲートおよびその使用
AU2009327267A1 (en) 2008-12-17 2011-07-14 Angiochem, Inc. Membrane type-1 matrix metalloprotein inhibitors and uses thereof
EP2421562B1 (en) 2009-04-20 2019-03-13 Angiochem Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US20100284921A1 (en) 2009-05-08 2010-11-11 Temple University - Of The Commonwealth System Of Higher Education Targeted nanoparticles for intracellular cancer therapy
WO2010141726A2 (en) 2009-06-03 2010-12-09 Dicerna Pharmaceuticals, Inc. Peptide dicer substrate agents and methods for their specific inhibition of gene expression
EP2440581A4 (en) 2009-06-11 2013-03-27 Angiochem Inc FUSION PROTEINS FOR THE DELIVERY OF GDNF AND BDNF TO THE CENTRAL NERVOUS SYSTEM
CN102596993A (zh) 2009-07-02 2012-07-18 安吉奥开米公司 多聚体肽结合物以及其应用
US20120107243A1 (en) 2009-07-14 2012-05-03 Mayo Foundation For Medical Education And Research Peptide-mediated non-covalent delivery of active agents across the blood-brain barrier
WO2011041897A1 (en) 2009-10-06 2011-04-14 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
US8530429B2 (en) 2009-11-24 2013-09-10 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
EP2333074A1 (en) 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
EA025443B1 (ru) 2010-03-08 2016-12-30 Слоан-Кеттеринг Институт Фор Кэнсер ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА КИНАЗЫ Cdc7 ГРАНАТИЦИНА B
EP2550285B1 (en) 2010-03-22 2017-07-19 President and Fellows of Harvard College Trioxacarcins and uses thereof
WO2011119608A1 (en) 2010-03-26 2011-09-29 University Of Tennessee Research Foundation Peptides that specifically target amyloid deposits
WO2011127580A1 (en) 2010-04-14 2011-10-20 National Research Council Of Canada Compositions and methods for brain delivery of analgesic peptides
WO2011153642A1 (en) 2010-06-10 2011-12-15 Angiochem Inc. Leptin and leptin analog conjugates and fusion proteins and uses thereof
BR112012033295A2 (pt) 2010-07-02 2016-10-11 Angiochem Inc polipeptídeos curtos e contendo d-aminoácido para conjugados terapêuticos e seu uso
US8218280B2 (en) 2010-07-08 2012-07-10 Schneider Electric USA, Inc. Secondary thermal sensor for primary conductors
WO2012018404A2 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
CN102406949B (zh) 2010-09-21 2013-05-29 复旦大学 一种靶向示踪的多模式诊断纳米影像药物
WO2012037687A1 (en) 2010-09-23 2012-03-29 Angiochem Inc. Therapeutic polypeptides and uses thereof
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2011329638C1 (en) 2010-11-18 2017-04-27 The General Hospital Corporation Novel compositions and uses of anti-hypertension agents for cancer therapy
CN102552928A (zh) 2010-12-19 2012-07-11 复旦大学 一种治疗脑部肿瘤的双级靶向递药系统及其制备方法
AR084824A1 (es) 2011-01-10 2013-06-26 Intellikine Inc Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
CN102614105A (zh) 2011-01-28 2012-08-01 复旦大学 一种脑靶向载两性霉素b聚合物胶束给药系统
EP2680820B1 (en) 2011-03-01 2022-11-02 2-BBB Medicines B.V. Advanced active liposomal loading of poorly water-soluble substances
WO2012135025A2 (en) 2011-03-28 2012-10-04 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
EP2952210A3 (en) 2011-04-07 2016-03-16 Emory University Compositions comprising saccharide binding moieties and methods for targeted therapy
EP2706989A1 (en) 2011-05-09 2014-03-19 Instituto Químico De Sarrià Polymeric nanoparticles for drug delivery
WO2013004716A1 (en) 2011-07-04 2013-01-10 Universität Basel Peptide beads
CN103946226A (zh) 2011-07-19 2014-07-23 无限药品股份有限公司 杂环化合物及其应用
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
EA027970B1 (ru) 2011-08-11 2017-09-29 ИНТЕЛЛАЙКИН, ЭлЭлСи Полиморфы ингибитора киназы
WO2013032591A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2013056096A1 (en) 2011-10-13 2013-04-18 Angiochem Inc. Polypeptide-opioid conjugates and uses thereof
KR102272498B1 (ko) 2011-10-27 2021-07-06 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
WO2013071272A1 (en) 2011-11-11 2013-05-16 Intellikine, Llc Kinase inhibitor polymorphs
AU2012344702A1 (en) 2011-12-01 2014-06-19 Angiochem Inc. Targeted lysosomal enzyme compounds
CN104136606A (zh) 2011-12-01 2014-11-05 安吉奥开米公司 靶向的艾杜糖-2-硫酸酯酶化合物
US9844598B2 (en) 2011-12-13 2017-12-19 Engeneic Molecular Delivery Pty Ltd Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
EA201491185A1 (ru) 2011-12-16 2015-05-29 Массачусетс Инститьют Оф Текнолоджи Полимеры альфа-аминоамидинов и их применение
WO2013120107A1 (en) 2012-02-09 2013-08-15 University Of Rochester Methods and compositions for treating a subject to inhibit hearing loss
EP2819686A4 (en) 2012-03-02 2016-05-25 Icahn School Med Mount Sinai PROTHYMOSIN ALPHA VARIANTS AND METHODS OF USE
EA031986B1 (ru) 2012-04-04 2019-03-29 Галозим, Инк. Способ и комбинация для лечения солидной раковой опухоли и набор, содержащий комбинацию
ES2905359T3 (es) 2012-04-26 2022-04-08 Univ Yale Moléculas de suministro de fármacos citotóxicos dirigidas al VIH (CDM-H), actividad citotóxica contra el virus de la inmunodeficiencia humana y métodos de uso

Also Published As

Publication number Publication date
CA2759129C (en) 2018-12-11
CA2759129A1 (en) 2010-10-28
WO2010121379A1 (en) 2010-10-28
EP2421562B1 (en) 2019-03-13
US20120122798A1 (en) 2012-05-17
ES2729261T3 (es) 2019-10-31
US9173891B2 (en) 2015-11-03
AU2010239069A1 (en) 2011-11-10
EP2421562A4 (en) 2014-12-10
JP2012524030A (ja) 2012-10-11
AU2010239069B2 (en) 2015-05-14
BRPI1015295A2 (pt) 2016-05-31
ZA201107626B (en) 2012-12-27
CN102510759A (zh) 2012-06-20
EP2421562A1 (en) 2012-02-29
MX2011011023A (es) 2012-01-20

Similar Documents

Publication Publication Date Title
RU2011146654A (ru) Способы лечения рака яичников с применением конъюгированного средства
Brown et al. Cisplatin-based chemotherapy of human cancers
Mehmood Review of Cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments
Liu et al. Inhibition of tumor growth in vitro by a combination of extracts from rosa roxburghii tratt and fagopyrum cymosum
Wang et al. Molecular mechanisms of chemoresistance in oral cancer
Karnthaler‐Benbakka et al. Tumor‐targeting of EGFR inhibitors by hypoxia‐mediated activation
RU2011142806A (ru) Комбинации пентамидина для лечения рака
RU2012137503A (ru) Лекарственный препарат для лечения и/или профилактики рака
RU2014108044A (ru) Фармацевтическая композиция для лечения и профилактики злокачественной опухоли
RU2014108049A (ru) Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
RU2014108045A (ru) Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
Chen et al. A new prospect in cancer therapy: targeting cancer stem cells to eradicate cancer
Soleyman-Jahi et al. In vitro assessment of antineoplastic effects of deuterium depleted water
RU2007104053A (ru) Лечение рака
RU2015141932A (ru) Аргининдеиминаза с пониженной перекрестной реактивностью к антителам adi-peg 20 для лечения рака
EA201892797A1 (ru) Наночастицы для доставки лекарственных средств и способы лечения лекарственно-резистентного рака
Yu et al. Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model
He et al. Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy
RU2015152785A (ru) Лечение злокачественной опухоли налтрексоном
Hu et al. Reversal effects of local anesthetics on P-glycoprotein-mediated cancer multidrug resistance
JP2017529366A5 (ru)
Wang et al. Regulatory mechanisms of annexin-induced chemotherapy resistance in cisplatin resistant lung adenocarcinoma
Qi et al. Cisplatin loaded multiwalled carbon nanotubes reverse drug resistance in NSCLC by inhibiting EMT
RU2009127775A (ru) Способ введения пегилированного липосомального доксорубицина
Imai et al. Efficacy and safety of carboplatin and etoposide combination chemotherapy for extrapulmonary neuroendocrine carcinoma: a retrospective case series

Legal Events

Date Code Title Description
FA94 Acknowledgement of application withdrawn (non-payment of fees)

Effective date: 20160704